Dr. Reddy's Laboratories Ltd.
http://www.drreddys.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dr. Reddy's Laboratories Ltd.
Reddy’s Settles On $7bn Revlimid But Natco Maintains The Lead
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.
Dr Reddy’s To Steer Russian COVID-19 Vaccine Plans In India
Dr Reddy’s combines forces with the Russian Direct Investment Fund for clinical trials and supply of Sputnik V in India, amid what it views as “very important” data points in early studies of the COVID-19 vaccine.
Dr Reddy’s And Perrigo Capitalize On Voltaren Switch
Seven months after GlaxoSmithKline’s Voltaren Arthritis Pain (diclofenac sodium) 1% topical gel was switched to non-prescription status in the US, two companies have begun shipping equivalent OTC versions to retailers.
Supply Chain Constraints ‘Will Limit Vascepa Threat’
Supply is the million-dollar question for Vascepa ANDA sponsors, with Dr Reddy’s and Hikma receiving a further green light to introduce their generics into the US market.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Aurigene Discovery Technologies
- OctoPlus N.V.
- Promius Pharma LLC
- Dr. Reddy's Research and Development B.V.
- Imperial Credit Private Limited
- Wockhardt Limited